Drug General Information
Drug ID	D04AEQ
Former ID	DIB002281
Drug Name	V81444
Indication	Parkinson's disease [ICD9: 332; ICD10:G20]		Phase 1/2	[524937]
Company	Vernalis
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Adenosine A2a receptor	Target Info	Antagonist	[532726]
KEGG Pathway	Rap1 signaling pathway
	Calcium signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Vascular smooth muscle contraction
	Parkinson's disease
	Alcoholism
Pathway Interaction Database	HIF-2-alpha transcription factor network
PathWhiz Pathway	Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
Reactome	NGF-independant TRKA activation
	Adenosine P1 receptors
	G alpha (s) signalling events
	Surfactant metabolism
WikiPathways	Nucleotide GPCRs
	Monoamine Transport
	GPCRs, Class A Rhodopsin-like
	NGF signalling via TRKA from the plasma membrane
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 524937	ClinicalTrials.gov (NCT02253745) Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
Ref 532726	Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.